Comparison of two α1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: A randomized crossover study

BJU International

Volumn 97, Issue 4, 2006, Pages 747-751

  Nishino, Yoshinori ^a   Masue, Takako ^a   Miwa, Kousei ^a   Takahashi, Yoshito ^a   Ishihara, Satoshi ^a   Deguchi, Takashi ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

BPH; LUTS; Naftopidil; Randomized crossover study; Tamsulosin hydrochloride

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; NAFTOPIDIL; TAMSULOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; NAPHTHALENE DERIVATIVE; PIPERAZINE DERIVATIVE; SULFONAMIDE;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; BLADDER NECK STENOSIS; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MALE; MICTURITION; NOCTURIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINARY FREQUENCY; URINARY TRACT DISEASE; URINARY URGENCY; URINE INCONTINENCE; URINE VOLUME; UROFLOWMETRY; COMPARATIVE STUDY; MICTURITION DISORDER; URODYNAMICS;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; CROSS-OVER STUDIES; HUMANS; MALE; NAPHTHALENES; PIPERAZINES; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; SULFONAMIDES; TREATMENT OUTCOME; URINATION DISORDERS; URODYNAMICS;

EID: 33644897341     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06030.x     Document Type: Article

References (23)

1. Yamanaka N Yamaguchi O Kameoka H et al. [Effect of KT-611 (Naftopidil) on the contraction of human prostatic tissue and its use in benign prostatic obstruction] Hinyokika Kiyo 1991 37 1759 72
2. Kawabe K Ueno A Takimoto Y Aso Y Kato H Use of an alpha 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. YM617 Clinical Study Group J Urol 1990 144 908 12
3. Pescalli N Sala V Sponer G Ceserani R Effects of naftopidil on some urodynamic parameters and arterial blood pressure in comparison with prazosin in conscious rats Pharmacol Res 1996 34 121 4
4. Yasuda K Yamanishi T Tojo M Nagashima K Akimoto S Shimazaki J Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies Prostate 1994 25 46 52
5. Yamaguchi O Fukaya Y Shiraiwa Y et al. Dose-dependent effects and clinical usefulness of naftopidil (KT-611) on urinary obstruction caused by benign prostatic hyperplasia - double-blind comparative study compared with placebo Kiso Rinsho 1997 31 1315 60
6. Yamanishi T Yasuda K Kamai T et al. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia Int J Urol 2004 11 501 9
7. Takei R Ikegaki I Shibata K Tsujimoto G Asano T Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors Jpn J Pharmacol 1999 79 447 54
8. Nasu K Moriyama N Kawabe K et al. Quantification and distribution of alpha1-adrenoceptor subtype mRNAs in human prostate: comparison of benign prostatic hypertrophied tissue and non-hypertrophied tissue Br J Pharmacol 1996 119 797 803
9. Smith MS Schambra UB Wilson KH Page SO Schwinn DA Alpha1-adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding alpha1-adrenergic receptor subtypes at four distinct levels Brain Res Mol Brain Res 1999 63 254 61
10. Malloy BJ Price DT Price RR et al. Alpha1-adrenergic receptor subtypes in human detrusor J Urol 1998 160 937 43
11. Kawabe K Ueno A Takimoto Y et al. Clinical evaluation of YM617 on bladder outlet obstruction associated with benign prostatic hypertrophy - a double-blind, multi-center study compared with placebo Jpn J Urol Surg 1991 4 231 42
12. Altman DG Clinical Trial In Practical Statistics for Medical Research Chapter 15. London Chapman & Hall 1991
13. Nakashima M Kanamaru M Uematsu T Phase I clinical study of naftopidil (KT-611), a new alpha1-adrenoceptor blocker J Clin Therap Med 1992 8 Suppl. 3 63 81
14. Tsunoo M Shishito A Soeishi Y Kobori M Shimoyama M Phase I clinical trial of YM617, a new alpha1-adrenoceptor antagonist - second report: a single oral dose of controlled release formulation in healthy male subjects J Clin Therap Med 1990 6 2529 51
15. Kojima Y Sasaki S Kohri K Shinoura H Tsujimoto G Correlation between alphaA1-adrenoreceptor subtype mRNA expression level and efficacy of naftopidil for BPH patients Neurourol Urodyn 2004 23 467 8
16. Chapple CR Smith D The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia Br J Urol 1994 73 117 23
17. Hampel C Dolber PC Smith MP et al. Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction J Urol 2002 167 1513 21
18. 1d- adrenergic receptor antagonist tamsulosin J Urol 2005 173 657 61
19. Sugaya K Nishijima S Miyazato M Ashitomi K Hatano T Ogawa Y Effect of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats Neurosci Lett 2002 328 74 6
20. Milsom I Abrams P Cardozo L Roberts RG Thuroff J Wein AJ How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study BJU Int 2001 87 760 6
21. Ouslander JG Management of overactive bladder N Engl J Med 2004 350 786 99
22. Athanasopoulos A Gyftopoulos K Giannitsas K Fisfis J Perimenis P Barbalias G Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study J Urol 2003 169 2253 6
23. Maruyama O Kawachi Y Hanazawa K et al. The efficacy of combination therapy comprising naftopidil plus anticholinergic for storage symptoms caused by benign prostatic hyperplasia Nishinihon J Urol 2004 66 746 54